UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported)
|
December 1,
2010
|
NEOPROBE CORPORATION
(Exact
name of registrant as specified in its charter)
Delaware
|
0-26520
|
31-1080091
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
of
incorporation)
|
File
Number)
|
Identification
No.)
|
425 Metro Place North, Suite 300, Columbus,
Ohio
|
43017
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant's
telephone number, including area code
|
(614)
793-7500
|
(Former name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item
5.02. Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
Kirby I. Bland, M.D. retired from his
position as a director of Neoprobe Corporation (the "Company"), effective
December 1, 2010. Dr. Bland recently assumed positions on certain
advisory panels for the National Institutes of Health ("NIH") and serves as an
officer in certain national surgical societies. Independence
guidelines for these organizations discourage, and in some cases prohibit,
members from holding decision making positions with for-profit entities such as
the Company. Dr. Bland therefore decided to retire from the Board to
avoid potential future conflicts of interest. Dr. Bland has, however,
agreed to continue to advise the Company through participation in the Company’s
Scientific Advisory Board. In this way, the Company believes it
will continue to benefit from the extensive experience of a world renowned
leader in the surgical oncology field. There were no matters of
disagreement between Dr. Bland and the Company concerning the Company’s
operations, policies or practices, which caused the decision of Dr. Bland to
retire from the Board.
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
Neoprobe
Corporation
|
|||
Date:
December 6, 2010
|
By:
|
/s/ Brent L.
Larson
|
|
Brent
L. Larson, Senior Vice President and
Chief
Financial Officer
|
|||
3